

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



A01
D2

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 5/00, 5/28, 5/24, 5/10, C07K 16/00, A61K 39/00		A1	(11) International Publication Number: WO 98/24884 (43) International Publication Date: 11 June 1998 (11.06.98)
(21) International Application Number: PCT/US97/21803 (22) International Filing Date: 1 December 1997 (01.12.97) (30) Priority Data: 08/758,417 2 December 1996 (02.12.96) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant: GENPHARM INTERNATIONAL [US/US]; Suite C, 855 California Avenue, Palo Alto, CA 94304 (US). (72) Inventors: LONBERG, Nils; 930 Edgecliff Way, Redwood City, CA 94061 (US). KAY, Robert, M.; 2127 Broadway #5, San Francisco, CA 94115 (US). (74) Agents: APPLE, Randolph, T. et al.; Townsend and Townsend and Crew LLP, 8th floor, Two Embarcadero Center, San Francisco, CA 94111-3834 (US).		Published <i>With international search report.</i>	

(54) Title: TRANSGENIC NON-HUMAN ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES

(57) Abstract

The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.

452 pages!
See Docs file

DIALOG(R) File 351:Derwent WPI
(c) 2001 Derwent Info Ltd. All rts. reserv.

011916396

WPI Acc No: 1998-333306/199829

XRAM Acc No: C98-103354

Hybridoma producing antibody specific for interleukin-8 - used to prevent efflux of neutrophils from vasculature, and treat reperfusion injury

Patent Assignee: GENPHARM INT (GENP-N)

Inventor: KAY R M; LONBERG N

Number of Countries: 078 Number of Patents: 003

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 9824884	A1	19980611	WO 97US21803	A	19971201	199829 B
AU 9856881	A	19980629	AU 9856881	A	19971201	199845
EP 942959	A1	19990922	EP 97953058	A	19971201	199943

WO 97US21803 A 19971201

Priority Applications (No Type Date): US 96758417 A 19961202

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 9824884 A1 E 452 C12N-005/00

Designated States (National): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LV MD MG MK MN MW NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

Designated States (Regional): AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW

AU 9856881 A C12N-005/00 Based on patent WO 9824884

EP 942959 A1 E C12N-005/00 Based on patent WO 9824884

Designated States (Regional): AL AT BE CH DE DK ES FI FR GB GR IE IT LI LU LV MC NL PT RO SE SI

Abstract (Basic): WO 9824884 A

A hybridoma comprising a B cell obtained from a transgenic mouse having a genome comprising a human heavy chain transgene and a human light chain transgene, the B cell being fused to an immortalised cell to generate a hybridoma, where the hybridoma produces a detectable amount of an immunoglobulin that specifically binds interleukin-8 (IL-8), is new.

Also claimed are: (1) a composition comprising a substantially pure immunoglobulin produced by the above hybridoma; (2) a composition comprising a substantially pure human monoclonal antibody (MAb), where the Ab has an affinity constant (Ka) of at least 2×10^9 M-1 for binding human IL-8, and where the immunoglobulin consists of: (a) a human light chain sequence composed of: (i) a light chain variable region having a polypeptide sequence which is substantially identical to a polypeptide sequence encoded by a human V-L gene segment and a human J-L segment; and (ii) a light chain constant region having a polypeptide sequence which is substantially identical to a polypeptide encoded by a C-L gene segment; and (b) a human heavy chain sequence composed of: (i) a heavy chain variable region having a polypeptide sequence which is substantially identical to a polypeptide sequence encoded by a human V-H segment optionally a D region and a human J-H segment; and (ii) a constant region having a polypeptide sequence which is substantially identical to a polypeptide sequence encoded by a human C-H gene segment; and (3) a method of suppressing a T-cell helper dependent immune response in a primate, comprising administering a therapeutically effective dose of a human monoclonal antibody having a Ka of at least 2×10^9 M-1 for binding human CD-4.

USE - The MAb can be used in a method for preventing efflux of neutrophils from vasculature in a patient. It can also be used in a method for treating reperfusion injury (both claimed). The CD4 binding Ab will be able to be used to reduce undesirable autoimmune reactions,

Title : Dialog

inflammatory responses and rejection of transplanted organs. The anti-IL-8 Abs can reduce tissue damage and prolong survival in animal models of acute adult respiratory distress syndrome (ARDS) and acid induced lung injury. The anti-IL-8 Abs can be used for the treatment of reperfusion injuries (especially to the lung and heart), vasculitis, septic shock, autoimmune diseases (including glomerulonephritis, inflammatory bowel disease, rheumatoid arthritis, and psoriasis), allergic reactions (e.g. asthma) and cystic fibrosis.

Dwg.0/98

Title Terms: HYBRIDOMA; PRODUCE; ANTIBODY; SPECIFIC; INTERLEUKIN; PREVENT; EFFLUX; TREAT; REPERFUSION; INJURY

Derwent Class: B04; D16

International Patent Class (Main): C12N-005/00

International Patent Class (Additional): A61K-039/00; C07K-016/00;
C12N-005/10; C12N-005/24; C12N-005/28

File Segment: CPI

Manual Codes (CPI/A-N): B04-F05; B04-G21; B14-C01; B14-G02C; D05-H11A1;
D05-H15

Chemical Fragment Codes (M1):

01 M423 M710 M903 N135 Q233 V754

02 M423 M710 M903 N135 Q233 V752

03 M423 M710 M903 P210 P420 P421 P423 P433 P520 P723 P731 P820 P822
P943 Q233 V600 V611

?

Status: Signing Off...

logoff

05feb01 06:45:08 User074485 Session D4568.2

\$14.85 0.631 DialUnits File351

\$4.47 1 Type(s) in Format 9

\$4.47 1 Types

\$19.32 Estimated cost File351

\$0.19 DIALNETE

\$19.51 Estimated cost this search

\$20.27 Estimated total session cost 0.835 DialUnits